Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
idarubicin
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(22)
News
Trials
Company:
Delta Farma, Desitin Pharma, Pfizer
Drug class:
DNA replication inhibitor
Related drugs:
‹
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
trastuzumab duocarmazine (6)
MEDI7247 (6)
ABBV-321 (6)
rovalpituzumab tesirine (5)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
IMGN632 (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
DHES0815A (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
ADCT-502 (0)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
trastuzumab duocarmazine (6)
MEDI7247 (6)
ABBV-321 (6)
rovalpituzumab tesirine (5)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
IMGN632 (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
DHES0815A (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
ADCT-502 (0)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
›
Associations
(22)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
cytarabine + methotrexate + idarubicin
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin
Sensitive
:
A2
cytarabine + methotrexate + idarubicin
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin
Sensitive
:
A2
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
FLT3-ITD mutation + ASXL1 mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation + ASXL1 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
DNMT3A mutation + ASXL1 mutation
Acute Myelogenous Leukemia
DNMT3A mutation + ASXL1 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
DNMT3A mutation + NRAS mutation
Acute Myelogenous Leukemia
DNMT3A mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
NPM1 mutation + SRSF2 mutation
Acute Myelogenous Leukemia
NPM1 mutation + SRSF2 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
FLT3 mutation + NRAS mutation
Acute Myelogenous Leukemia
FLT3 mutation + NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
DNMT3A mutation
Acute Myelogenous Leukemia
DNMT3A mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
ASXL1 mutation
Acute Myelogenous Leukemia
ASXL1 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
NRAS mutation
Acute Myelogenous Leukemia
NRAS mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
cytarabine + idarubicin
Sensitive: C3 – Early Trials
cytarabine + idarubicin
Sensitive
:
C3
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
DNMT3A mutation + FLT3-ITD mutation
Acute Myelogenous Leukemia
DNMT3A mutation + FLT3-ITD mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
cytarabine + idarubicin
Resistant: C3 – Early Trials
cytarabine + idarubicin
Resistant
:
C3
NUP98-PRRX1 fusion
Acute Myelogenous Leukemia
NUP98-PRRX1 fusion
Acute Myelogenous Leukemia
cytarabine + idarubicin
Sensitive: C4 – Case Studies
cytarabine + idarubicin
Sensitive
:
C4
cytarabine + idarubicin
Sensitive: C4 – Case Studies
cytarabine + idarubicin
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login